MOVE TRIAL: A Phase 3, Efficacy and Safety Study of Oral Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)
Phase of Trial: Phase III
Latest Information Update: 05 Dec 2017
At a glance
- Drugs Palovarotene (Primary)
- Indications Fibrodysplasia ossificans progressiva
- Focus Registrational; Therapeutic Use
- Acronyms MOVE
- Sponsors Clementia Pharmaceuticals
- 28 Nov 2017 Status changed from not yet recruiting to recruiting.
- 13 Nov 2017 According to Clementia Pharmaceuticals media release, first patient expected to enroll by the end of 2017.
- 03 Nov 2017 Planned initiation date changed from 1 Oct 2017 to 1 Nov 2017.